88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Haier Biomedical Publishes 2025 Sustainability Report: Committed to Building a Platform for Technology, Industry and Social Responsibility QINGDAO, China , May 20, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has released its 2025 Sustainability Report, providing a comprehensive ... 2026-05-20T Biotechnology Computer/Electronics Environmental Products & Services Health Care/Hospital
Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research Collaboration expands research of new delivery platform beyond liver tissues supporting potential preclinical development and strengthens Singapore's position as a biomedical innovation hub ... 2026-05-20T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline SHANGHAI and HONG KONG , May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ... 2026-05-20T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening ... 2026-05-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC NANJING, China , May 19, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB ... 2026-05-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases F inancing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor ... 2026-05-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities observed. TLX101-Tx is also the subject of a pivotal ... 2026-05-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing NORWALK, Conn. , May 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics' ... 2026-05-19T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Major breakthrough of Sanyou Biopharmaceuticals AI-STAL SHANGHAI , May 18, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap ... 2026-05-18T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial - BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - ... 2026-05-18T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved